Formaldehyde
Identification
- Name
- Formaldehyde
- Accession Number
- DB03843
- Description
A highly reactive aldehyde gas formed by oxidation or incomplete combustion of hydrocarbons. In solution, it has a wide range of uses: in the manufacture of resins and textiles, as a disinfectant, and as a laboratory fixative or preservative. Formaldehyde solution (formalin) is considered a hazardous compound, and its vapor toxic. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p717)
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Structure
Structure for Formaldehyde (DB03843)
- Weight
- Average: 30.026
Monoisotopic: 30.010564686 - Chemical Formula
- CH2O
- Synonyms
- Formaldehído
- Formaldehyd
- Formaldehyde
- Formaldehyde solution
- Formalin
- Formic aldehyde
- Formol
- Methanal
- Methyl aldehyde
- Methylene oxide
- Oxomethane
- Oxomethylene
- Oxymethylene
- Paraform
- External IDs
- NSC-298885
Pharmacology
- Indication
Use for drying skin before or after surgical removal of warts or where dryness is required.
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UD-alanyl-D-alanine carboxypeptidase Not Available Streptomyces sp. (strain R61) UHematopoietic stem cells Not Available Humans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
Acute oral toxicity (LD50): 42 mg/kg [Mouse].
- Affected organisms
- Not Available
- Pathways
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataCalcium carbimide The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Formaldehyde. Disulfiram The risk or severity of adverse effects can be increased when Disulfiram is combined with Formaldehyde. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- No interactions found.
Products
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataForma-Ray Liquid .2 mL/59mL Topical Gordon Laboratories 2010-07-15 Not applicable US 
Formadon Liquid 0.1 mL/59mL Topical Gordon Laboratories 2010-06-21 Not applicable US Formalaz Liquid 100 mg/1g Topical River's Edge Pharmaceuticals, LLC 2006-09-16 2012-10-31 US Formaldehyde Solution 100 mg/1mL Topical Rochester Pharmaceuticals 2011-04-27 2019-07-08 US Formaldehyde Liquid 8.505 g/88.72059mL Topical Breckenridge Pharmaceutical, Inc. 2009-01-01 2010-10-31 US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image British Army Foot Pwr Formaldehyde (.75 mg) + Boric acid (6 mg) + Salicylic acid (3 mg) + Zinc oxide (6 mg) Powder Topical Regal Pharms, Division Of Bradcan Corporation 1980-12-31 2001-07-11 Canada 
Root Canal Therapy Formaldehyde (19 %) + Cresol (35 %) Liquid Dental Amd Medicom Inc 1999-11-26 2006-08-03 Canada T.R.U.E. Test Thin-Layer Rapid Use Patch Test Formaldehyde (146 ug/48h) + 2,2'-Dibenzothiazyl disulfide (20 ug/48h) + 2-mercaptobenzothiazole (61 ug/48h) + 4-(Isopropylamino)diphenylamine (10 ug/48h) + Bacitracin (486 ug/48h) + Balsam of Peru (648 ug/48h) + Benzocaine (378 ug/48h) + Benzylparaben (162 ug/48h) + Bisphenol A diglycidyl ether (32 ug/48h) + Bromothalonil (4 ug/48h) + Bronopol (203 ug/48h) + Budesonide (0.8 ug/48h) + Butylparaben (162 ug/48h) + Chlorquinaldol (77 ug/48h) + Cinchocaine hydrochloride (66 ug/48h) + Cinnamaldehyde (41 ug/48h) + Cinnamyl alcohol (63 ug/48h) + Clioquinol (77 ug/48h) + Cobalt chloride hexahydrate (4 ug/48h) + Diazolidinylurea (446 ug/48h) + Potassium dichromate (15.7 ug/48h) + Dipentamethylenethiuram disulfide (5.5 ug/48h) + Diphenylguanidine (68 ug/48h) + Disperse Blue 106 (41 ug/48h) + Disulfiram (5.5 ug/48h) + Ditiocarb zinc (68 ug/48h) + Ethyl hydroxybenzoate (162 ug/48h) + Ethylenediamine (18 ug/48h) + Eugenol (41 ug/48h) + Evernia prunastri (81 ug/48h) + Geraniol (81 ug/48h) + Hydrocortisone butyrate (16 ug/48h) + Hydroxycitronellal (63 ug/48h) + Imidurea (486 ug/48h) + Isoeugenol (17 ug/48h) + Lanolin alcohols (810 ug/48h) + Methylchloroisothiazolinone (3 ug/48h) + Methylparaben (162 ug/48h) + Morpholinylmercaptobenzothiazole (20 ug/48h) + N,N'-diphenyl-1,4-phenylenediamine (25 ug/48h) + N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine (25 ug/48h) + Neomycin sulfate (486 ug/48h) + Nickel sulfate hexahydrate (36 ug/48h) + Parthenolide (2 ug/48h) + Propylparaben (162 ug/48h) + Quaternium-15 (81 ug/48h) + Rosin (972 ug/48h) + Sodium aurotiosulfate (23 ug/48h) + Tetracaine hydrochloride (66 ug/48h) + Tetramethylthiuram monosulfide (5.5 ug/48h) + Thimerosal (6 ug/48h) + Thiohexam (20 ug/48h) + Thiram (5.5 ug/48h) + Tixocortol pivalate (2 ug/48h) + Zinc dibutyldithiocarbamate (68 ug/48h) + alpha-Amyl cinnamaldehyde (17 ug/48h) + p-Phenylenediamine (65 ug/48h) + p-tert-Butylphenol-formaldehyde resin (low molecular weight) (36 ug/48h) Cutaneous SmartPractice Denmark ApS 2012-03-01 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Forma-Ray Formaldehyde (.2 mL/59mL) Liquid Topical Gordon Laboratories 2010-07-15 Not applicable US Formadon Formaldehyde (0.1 mL/59mL) Liquid Topical Gordon Laboratories 2010-06-21 Not applicable US Formalaz Formaldehyde (100 mg/1g) Liquid Topical River's Edge Pharmaceuticals, LLC 2006-09-16 2012-10-31 US Formaldehyde Formaldehyde (100 mg/1mL) Solution Topical Rochester Pharmaceuticals 2011-04-27 2019-07-08 US Formaldehyde Formaldehyde (8.505 g/88.72059mL) Liquid Topical Breckenridge Pharmaceutical, Inc. 2009-01-01 2010-10-31 US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as carbonyl compounds. These are organic compounds containing a carbonyl group, with the general structure RC(=O)R', where R=organyl, R'=H, N, O, organyl group or halide group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbonyl compounds
- Direct Parent
- Carbonyl compounds
- Alternative Parents
- Organic oxides / Hydrocarbon derivatives
- Substituents
- Aliphatic acyclic compound / Carbonyl group / Hydrocarbon derivative / Organic oxide
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- one-carbon compound, aldehyde (CHEBI:16842) / an <i>n</i>-alkanal (FORMALDEHYDE)
Chemical Identifiers
- UNII
- 1HG84L3525
- CAS number
- 50-00-0
- InChI Key
- WSFSSNUMVMOOMR-UHFFFAOYSA-N
- InChI
- InChI=1S/CH2O/c1-2/h1H2
- IUPAC Name
- formaldehyde
- SMILES
- [H]C([H])=O
References
- Synthesis Reference
Walter Hasselman, Jr., "Process for the preparation of phenol-urea-formaldehyde condensation products." U.S. Patent US4345061, issued August, 1926.
US4345061- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0001426
- KEGG Drug
- D00017
- KEGG Compound
- C00067
- PubChem Compound
- 712
- PubChem Substance
- 46505094
- ChemSpider
- 692
- 314636
- ChEBI
- 16842
- ChEMBL
- CHEMBL1255
- PharmGKB
- PA449703
- Guide to Pharmacology
- GtP Drug Page
- PDBe Ligand
- FOR
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Formaldehyde
- PDB Entries
- 1jlx / 1jly / 1oao / 1pw1 / 1r1l / 1rdg / 1wyk / 2rus / 2wyl / 3etc … show 14 more
- MSDS
- Download (82.2 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Tick-borne Encephalitis (TBE) 1 3 Completed Prevention Tick-borne Encephalitis (TBE) 1 Not Available Completed Not Available Tick-borne Encephalitis (TBE) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- AIG Technologies Inc.
- Breckenridge Pharmaceuticals
- DSHealthcare Inc.
- Epic Pharma LLC
- Gordon Laboratories
- Harmony Laboratories Inc.
- Moyco Union Broach
- PEDiNOL
- River's Edge Pharmaceuticals
- Dosage Forms
Form Route Strength Powder Topical Liquid Topical .2 mL/59mL Liquid Topical 0.1 mL/59mL Liquid Topical 100 mg/1g Liquid Topical 8.505 g/88.72059mL Solution Topical 100 mg/1mL Solution Topical 100 g/100g Solution Topical 37 g/100mL Solution Topical 37 mL/100mL Solution Topical 10 mL/100mL Liquid Dental - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Gas
- Experimental Properties
Property Value Source melting point (°C) -92 °C PhysProp boiling point (°C) -19.1 °C PhysProp water solubility 4E+005 mg/L (at 20 °C) PICKRELL,JA ET AL. (1983) logP 0.35 HANSCH,C ET AL. (1995) pKa 13.3 (at 25 °C) SERJEANT,EP & DEMPSEY,B (1979) - Predicted Properties
Property Value Source Water Solubility 198.0 mg/mL ALOGPS logP -0.68 ALOGPS logP -0.47 ChemAxon logS 0.82 ALOGPS pKa (Strongest Basic) -8.1 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 1 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 17.07 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 6.31 m3·mol-1 ChemAxon Polarizability 2.58 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9757 Blood Brain Barrier + 0.982 Caco-2 permeable + 0.7834 P-glycoprotein substrate Non-substrate 0.8663 P-glycoprotein inhibitor I Non-inhibitor 0.9633 P-glycoprotein inhibitor II Non-inhibitor 0.9831 Renal organic cation transporter Non-inhibitor 0.9145 CYP450 2C9 substrate Non-substrate 0.8628 CYP450 2D6 substrate Non-substrate 0.9157 CYP450 3A4 substrate Non-substrate 0.8203 CYP450 1A2 substrate Non-inhibitor 0.8503 CYP450 2C9 inhibitor Non-inhibitor 0.9662 CYP450 2D6 inhibitor Non-inhibitor 0.9735 CYP450 2C19 inhibitor Non-inhibitor 0.9531 CYP450 3A4 inhibitor Non-inhibitor 0.977 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9443 Ames test AMES toxic 0.645 Carcinogenicity Carcinogens 0.6567 Biodegradation Ready biodegradable 0.7562 Rat acute toxicity 2.5082 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9573 hERG inhibition (predictor II) Non-inhibitor 0.9823
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets
- Kind
- Protein
- Organism
- Streptomyces sp. (strain R61)
- Pharmacological action
- Unknown
- General Function
- Serine-type d-ala-d-ala carboxypeptidase activity
- Specific Function
- Catalyzes distinct carboxypeptidation and transpeptidation reactions during the last stages of wall peptidoglycan synthesis. Mistaking a beta-lactam antibiotic molecule for a normal substrate (i.e....
- Gene Name
- Not Available
- Uniprot ID
- P15555
- Uniprot Name
- D-alanyl-D-alanine carboxypeptidase
- Molecular Weight
- 42916.725 Da
2. Hematopoietic stem cells
Unknown
References
- Goldstein BD: Hematological and toxicological evaluation of formaldehyde as a potential cause of human leukemia. Hum Exp Toxicol. 2011 Jul;30(7):725-35. doi: 10.1177/0960327110381682. Epub 2010 Aug 20. [PubMed:20729258]
Drug created on June 13, 2005 07:24 / Updated on June 12, 2020 10:52
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates